-transparent.png){kind=logo}
Transforming growth factors type-beta and dexamethasone attenuate group II phospholipase A2 gene expression by interleukin-1 and forskolin in rat mesangial cells. 1992
H Mühl, and
T Geiger, and
W Pignat, and
F Märki, and
H van den Bosch, and
N Cerletti, and
D Cox, and
G McMaster, and
K Vosbeck, and
J Pfeilschifter
Department of Pharmacology, Biocenter, University of Basel, Switzerland.
Treatment of rat mesangial cells with interleukin-1 beta (IL-1 beta) and forskolin induced, in a synergistic fashion, the expression of group II phospholipase A2 (PLA2) mRNA, with subsequent increased synthesis and secretion of PLA2. In contrast, interleukin-6 did not increase PLA2 mRNA levels of PLA2 activity. Transforming growth factor (TGF) beta 1, TGF beta 2 and TGF beta 3 equipotently attenuated the IL-1 beta- and forskolin-induced elevation of PLA2 mRNA, as well as PLA2 synthesis and secretion. The glucocorticoid dexamethasone only partially suppressed the IL-1 beta- and forskolin-induced elevation of PLA2 mRNA, but totally inhibited PLA2 synthesis and secretion.
Related Publications
H Mühl, and
T Geiger, and
W Pignat, and
F Märki, and
H van den Bosch, and
N Cerletti, and
D Cox, and
G McMaster, and
K Vosbeck, and
J Pfeilschifter
April 1996,
The Biochemical journal,
H Mühl, and
T Geiger, and
W Pignat, and
F Märki, and
H van den Bosch, and
N Cerletti, and
D Cox, and
G McMaster, and
K Vosbeck, and
J Pfeilschifter
May 1992,
The Journal of biological chemistry,
H Mühl, and
T Geiger, and
W Pignat, and
F Märki, and
H van den Bosch, and
N Cerletti, and
D Cox, and
G McMaster, and
K Vosbeck, and
J Pfeilschifter
March 1997,
Biochimica et biophysica acta,
H Mühl, and
T Geiger, and
W Pignat, and
F Märki, and
H van den Bosch, and
N Cerletti, and
D Cox, and
G McMaster, and
K Vosbeck, and
J Pfeilschifter
January 1991,
Biochemical and biophysical research communications,
H Mühl, and
T Geiger, and
W Pignat, and
F Märki, and
H van den Bosch, and
N Cerletti, and
D Cox, and
G McMaster, and
K Vosbeck, and
J Pfeilschifter
June 1997,
British journal of pharmacology,
H Mühl, and
T Geiger, and
W Pignat, and
F Märki, and
H van den Bosch, and
N Cerletti, and
D Cox, and
G McMaster, and
K Vosbeck, and
J Pfeilschifter
February 1994,
The Journal of biological chemistry,
H Mühl, and
T Geiger, and
W Pignat, and
F Märki, and
H van den Bosch, and
N Cerletti, and
D Cox, and
G McMaster, and
K Vosbeck, and
J Pfeilschifter
October 1991,
Biochemical and biophysical research communications,
H Mühl, and
T Geiger, and
W Pignat, and
F Märki, and
H van den Bosch, and
N Cerletti, and
D Cox, and
G McMaster, and
K Vosbeck, and
J Pfeilschifter
June 1996,
European journal of pharmacology,
H Mühl, and
T Geiger, and
W Pignat, and
F Märki, and
H van den Bosch, and
N Cerletti, and
D Cox, and
G McMaster, and
K Vosbeck, and
J Pfeilschifter
November 1993,
FEBS letters,
H Mühl, and
T Geiger, and
W Pignat, and
F Märki, and
H van den Bosch, and
N Cerletti, and
D Cox, and
G McMaster, and
K Vosbeck, and
J Pfeilschifter
March 1997,
Biochimica et biophysica acta,
